Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-β via Smad3 acetylation.

Nature communications - 19 Nov 2022

Osseni Alexis, Ravel-Chapuis Aymeric, Belotti Edwige, Scionti Isabella, Gangloff Yann-Gaël, Moncollin Vincent, Mazelin Laetitia, Mounier Remi, Leblanc Pascal, Jasmin Bernard J, Schaeffer Laurent

Abstract excerpt

The absence of dystrophin in Duchenne muscular dystrophy disrupts the dystrophin-associated glycoprotein complex resulting in skeletal muscle fiber fragility and atrophy, associated with fibrosis as well as microtubule and neuromuscular junction disorganization. The specific, non-conventional cytoplasmic histone deacetylase 6 (HDAC6) was recently shown to regulate acetylcholine receptor distribution and muscle...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Dystrophin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fibrosis

Share to Histone Deacetylase Inhibitors

Share to Mice, Inbred mdx

Share to Muscular Atrophy

Share to Muscular Dystrophy, Duchenne

Share to Transforming Growth Factor beta

Source

Open in PubMed Open full text

Identifiers

PMID: 36402791
DOI: 10.1038/s41467-022-34831-3
PMCID: PMC9675748

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-β via Smad3 acetylation.PMID 36402791Read ↗

Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophySemantic proximity Read ↗

Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular DystrophiesSemantic proximity Read ↗

Histone deacetylase inhibition with givinostat: a multi-targeted mode of action with the potential to halt the pathological cascade of Duchenne muscular dystrophySemantic proximity Read ↗

Histone Deacetylase Inhibitors in the Treatment of Muscular Dystrophies: Epigenetic Drugs for Genetic DiseasesSemantic proximity Read ↗

Combining SMN2 splicing modifiers with HDAC6 inhibition greatly improves muscle function and survival in Spinal Muscular AtrophySemantic proximity Read ↗

HDAC5-mediated Smad7 silencing through MEF2A is critical for fibroblast activation and hypertrophic scar formationSemantic proximity Read ↗

The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity.Semantic proximity Read ↗

HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.Semantic proximity Read ↗

The therapeutic hope for HDAC6 inhibitors in malignancy and chronic diseaseSemantic proximity Read ↗

Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory DiseasesSemantic proximity Read ↗

HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?Semantic proximity Read ↗

Inhibition of HDAC6 activity in kidney diseases: a new perspectiveSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.